Nitrite Effects on Cardiac Muscle in CABG
Coronary Artery Disease, Atherosclerosis, Vascular Diseases
About this trial
This is an interventional basic science trial for Coronary Artery Disease
Eligibility Criteria
Inclusion Criteria:
Males or females aged >18years scheduled to undergo coronary artery bypass grafting.
Exclusion Criteria:
Inability to read and understand the consent form and patient information leaflet Pregnancy and any woman of child bearing potential Patients with Type I diabetes Significant medical, surgical or psychiatric disease that in the opinion of the patient's attending physician would affect subject safety and participation in the trial including severe heart failure (NYHAIII-IV and EF<40%) and severe renal impairment (requiring dialysis).
Unstable coronary syndrome (within 2 weeks) Known glucose-6-phosphate dehydrogenase (G6PD) deficiency or G6PD deficiency measured at screening in males of African, Asian or Mediterranean decent.
Receipt of an investigational drug or biological agent within the 4 weeks prior to study entry or 5 times the drug half-life, whichever is the longer.
Intended heart valve surgery or additional surgery or redo-CABG surgery.
Sites / Locations
- Aberdeen Royal Infirmary
- Papworth HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
sodium nitrite 24hours before
sodium nitrite 30minutes before
0.9% sodium chloride
10umol/min intravenous sodium nitrite for 30minutes at 1ml/min over a period of 30minutes, 24 hours prior to CABG surgery
10umol/min intravenous sodium nitrite for 30minutes at 1ml/min over a period of 30minutes, 30 minutes prior to CABG surgery
Intravenous normal (0.9%) sodium chloride infused at 1ml/min